Working with industry; the last step in the translational journey or the first step in discovering something new? For scientists in the MRC Protein Phosphorylation and Ubiquitylation Unit (MRC PPU) at the University of Dundee it’s both. Assistant director Dr Rob Ford gives the inside track on PPU’s award-winning industry collaboration.
Scientists at MRC PPU work hard to find and test new disease processes that can be targeted by drugs. Their aim is two-fold; to help pharmaceutical companies develop drugs to match the targets they discover, and to develop better treatments for neurodegenerative diseases, cancer, high blood pressure and immune system disorders.
Last month PPU played host to the 50th meeting of the Division of Signal Transduction Therapy (DSTT). DSTT is a unique collaboration between scientists in the MRC unit, the University of Dundee’s College of Life Sciences and six of the world’s leading pharmaceutical companies; AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Janssen Pharmaceutica, Merck Serono and Pfizer. Read more